Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.
about
Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies.Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat.Pathophysiology of GHRH-growth hormone-IGF1 axis in HIV/AIDS.Insulin resistance, lipodystrophy and cardiometabolic syndrome in HIV/AIDS.Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV.Cardiovascular risk and dyslipidemia among persons living with HIV: a review.Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects.Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.
P2860
Q35072510-06E9CFD2-A74C-4A6D-8595-3B7CC5274EBBQ35803315-023FAF97-8F7A-4889-AA10-DF632CDD1616Q38105267-CEABBA9E-3CB4-4C8B-ADF2-1D200784FBC0Q38108736-EFAFBB05-BB06-4E30-BBBA-BBC4F6321660Q38612748-38A9CE0C-2B9F-4F07-A10F-9BBEEB5F5D78Q40100018-FA7D74F6-3FD0-4DB1-AEB9-A7FD21D1EAA7Q41037305-EDF45BB2-C078-459C-A69B-689E07E51741Q41683105-3300AF7E-566B-4721-A5B6-39037E6540FD
P2860
Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Reduction in visceral adiposit ...... atients receiving tesamorelin.
@ast
Reduction in visceral adiposit ...... atients receiving tesamorelin.
@en
Reduction in visceral adiposit ...... atients receiving tesamorelin.
@nl
type
label
Reduction in visceral adiposit ...... atients receiving tesamorelin.
@ast
Reduction in visceral adiposit ...... atients receiving tesamorelin.
@en
Reduction in visceral adiposit ...... atients receiving tesamorelin.
@nl
prefLabel
Reduction in visceral adiposit ...... atients receiving tesamorelin.
@ast
Reduction in visceral adiposit ...... atients receiving tesamorelin.
@en
Reduction in visceral adiposit ...... atients receiving tesamorelin.
@nl
P2093
P2860
P356
P1476
Reduction in visceral adiposit ...... patients receiving tesamorelin
@en
P2093
Christian Marsolais
Graziella Soulban
Hani Assaad
Josée Morin
Julian Falutz
Ralph Turner
Steven K Grinspoon
Takara L Stanley
P2860
P304
P356
10.1093/CID/CIS251
P407
P577
2012-04-10T00:00:00Z